GRAI-MATTER-LABS
14.9.2021 09:02:12 CEST | Business Wire | Press release
GrAI Matter Labs (GML), a pioneer of brain-inspired computing solutions, announced today that it has entered a partnership with ERM Automatismes (ERM), a French market leader for didactic solutions in technological and professional training for 30 years, to create a ROS2-based robotics education kit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005311/en/
The Life-Ready AI Kit for Education combines robotics with brain-inspired AI as the key ingredient for Industry 4.0. The kit is comprised of a robot arm with a 2D/3D camera for visual perception, and a GML GrAI VIP platform integrated with an ADLINK I-Pi SMARC module. The ERM curriculum includes modules for grasping, regression, classification and more. It was developed with teachers from the French academy, universities, and a community of AI specialists to offer a very practical and easy to use model for teachers and students.
GML and ERM will showcase the education kit at the SIDO Fair in Lyon starting on 22nd of September. This unique kit, using GML's “Life-Ready AI” chip, GrAI VIP will demonstrate a real-life application of classifying agricultural products on a conveyor belt.
“We are delighted to be collaborating with ERM to teach our new generation of engineers cutting edge AI technologies. The students will learn to apply energy efficient machine-learning algorithms in an industrial context and help to kickstart a Life-Ready AI ecosystem which helps to save time, money and vital natural resources for Industry 4.0,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Cyril Liotard, CEO of ERM, is excited about the partnership, saying “with GrAI Matter Labs, we are expanding our existing portfolio with Life-Ready AI technology. GML offers a one-of-a-kind brain-inspired computing architecture that has never been seen before in education; that is why we are thrilled to collaborate with GML, and academia to achieve this goal together.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About ERM Automatismes
ERM Automatismes, founded in 1990, is a French company that provides technical systems and services in education, robotics, Fab&Test, and energy; and has developed didactic solutions for technological training as well as robotic and mechatronic solutions for the food industry. ERM provides a wide range of manufacturing and testing solutions to meet the growing needs of industrial customers, schools, colleges, universities, and engineering schools, as well as local authorities, municipalities, departments, and regions.
For more information, please visit https://www.erm-automatismes.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005311/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom